Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00576641 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma
A Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00576641 is a Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 22 participants.
The verdict
NCT00576641, a Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of the Dendritic Cell Immunotherapy study for patients with glioblastoma and/or brainstem glioma is to determine whether in patients with malignant brain tumors, dendritic cells injected peripherally can reactivate the immune system against the brain tumor.
Interventions
- BIOLOGICAL autologous dendritic cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00576641
The ClinicalTrials.gov registry entry for NCT00576641 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which autologous dendritic cells is the first listed.
NCT00576641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00576641 about?
NCT00576641 is a clinical study titled "Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma". The purpose of the Dendritic Cell Immunotherapy study for patients with glioblastoma and/or brainstem glioma is to determine whether in patients with malignant brain tumors, dendritic cells injected peripherally can reactivate the immune system against the brain tumor.
What is the current status of trial NCT00576641?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00576641?
The interventions under investigation include: autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00576641?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.